Literature DB >> 23869052

Species distribution and antifungal susceptibility of bloodstream fungal isolates in paediatric patients in Mexico: a nationwide surveillance study.

Gloria M González1, Rogelio de J Treviño-Rangel, José P Palma-Nicolás, César Martínez, J Gerardo González, Jacobo Ayala, Amílcar Caballero, Rayo Morfín-Otero, E Rodríguez-Noriega, Fernando Velarde, Elba P Ascencio, Juan C Tinoco, Jorge A Vázquez, Manuel A Cano, Nidia León-Sicairos, Rocío González, Joaquín Rincón, Miguel A Elías, Alexandro Bonifaz.   

Abstract

OBJECTIVES: To establish the species distribution and in vitro susceptibilities of 358 bloodstream fungal isolates from paediatric patients in Mexico.
METHODS: Isolates were collected during a 2 year surveillance programme in 14 medical centres in 10 Mexican states. A molecular approach was used to determine the Candida parapsilosis species complex. In vitro susceptibility to amphotericin B, fluconazole, voriconazole, itraconazole, posaconazole, caspofungin, anidulafungin and micafungin was determined according to CLSI procedures. Species-specific clinical breakpoints for fluconazole, voriconazole and echinocandins were applied.
RESULTS: Candida spp. accounted for 98.33% of fungaemias, including 127 Candida albicans isolates, 127 C. parapsilosis complex isolates (121 C. parapsilosis sensu stricto, 4 Candida orthopsilosis and 2 Candida metapsilosis strains) and 72 Candida tropicalis isolates. C. albicans and C. parapsilosis complex were the species predominant in neonates (48 cases each; 41.02%). C. parapsilosis complex was also the predominant species in patients 1 month to <2 years of age (P = 0.007). In contrast, C. albicans was the most frequent species in patients aged 2 to <12 years (P = 0.003). Antifungal resistance was rare among the subset of isolates. Candida glabrata showed the highest resistance rate to amphotericin B (1/9 isolates), fluconazole (1/9 isolates) and itraconazole (2/9 isolates).
CONCLUSIONS: The species distribution differed with the age of the patients, with C. albicans and C. parapsilosis complex being the most commonly isolated species. C. glabrata showed the highest resistance rate to amphotericin B, fluconazole and itraconazole. This is the first study of fungaemia episodes in Mexican children.

Entities:  

Keywords:  Candida albicans; Candida parapsilosis complex; Candida tropicalis; antifungal in vitro susceptibility; fungaemia

Mesh:

Substances:

Year:  2013        PMID: 23869052     DOI: 10.1093/jac/dkt283

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Identification of Candida parapsilosis Sensu Lato in Pediatric Patients and Antifungal Susceptibility Testing.

Authors:  Maria Emilia Cattana; Catiana Dudiuk; Mariana Fernández; Florencia Rojas; Liliana Alegre; Susana Córdoba; Guillermo Garcia-Effron; Gustavo Giusiano
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

Review 2.  Epidemiology of fungal infections in China.

Authors:  Min Chen; Yuan Xu; Nan Hong; Yali Yang; Wenzhi Lei; Lin Du; Jingjun Zhao; Xia Lei; Lin Xiong; Langqi Cai; Hui Xu; Weihua Pan; Wanqing Liao
Journal:  Front Med       Date:  2018-01-11       Impact factor: 4.592

3.  Three clustered cases of candidemia caused by Candida quercitrusa and mycological characteristics of this novel species.

Authors:  Meng Xiao; He Wang; Juan Lu; Sharon C-A Chen; Fanrong Kong; Xiao-Jun Ma; Ying-Chun Xu
Journal:  J Clin Microbiol       Date:  2014-04-02       Impact factor: 5.948

4.  Candidemia due to uncommon Candida species in children: new threat and impacts on outcomes.

Authors:  Ming-Horng Tsai; Jen-Fu Hsu; Lan-Yan Yang; Yu-Bin Pan; Mei-Yin Lai; Shih-Ming Chu; Hsuan-Rong Huang; Ming-Chou Chiang; Ren-Huei Fu; Jang-Jih Lu
Journal:  Sci Rep       Date:  2018-10-15       Impact factor: 4.379

5.  Clinical and microbiological characteristics, and impact of therapeutic strategies on the outcomes of children with candidemia.

Authors:  Ming-Horng Tsai; Jen-Fu Hsu; Shih-Ming Chu; Pey-Jium Chang; Mei-Yin Lai; I-Hsyuan Wu; Hsuan-Rong Huang; Ming-Chou Chiang; Ren-Huei Fu; Jang-Jih Lu
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.